Theriva Biologics KOL Event on Advancing Unique Oncolytic Virus Therapeutics
About The Event
Join us for a discussion with immunotherapy experts Michael Aaron Morse, MD (Duke University School of Medicine) and Arsen Osipov, MD (Cedars-Sinai Medical Center), who will provide an overview of the oncolytic virus landscape and the encouraging data that positions Theriva Biologics’ novel oncolytic adenovirus (OV) platform at the forefront of development to address devastating cancers with high unmet need. The discussion will also include recent findings from independent research highlighting the market opportunities for pancreatic ductal adenocarcinoma (PDAC).
VCN-01, Theriva’s lead clinical-stage drug candidate, is an intravenous, oncolytic adenovirus designed to break down the tumor stroma. Theriva Biologics’ upcoming Phase 2 clinical trial, VIRAGE, will evaluate VCN-01 in combination with standard-of-care chemotherapy gemcitabine/nab-paclitaxel in patients with PDAC.
An audience Q&A session will follow the formal discussion.